1. Home
  2. DAWN vs ATEC Comparison

DAWN vs ATEC Comparison

Compare DAWN & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • ATEC
  • Stock Information
  • Founded
  • DAWN 2018
  • ATEC 1990
  • Country
  • DAWN United States
  • ATEC United States
  • Employees
  • DAWN N/A
  • ATEC N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • ATEC Medical/Dental Instruments
  • Sector
  • DAWN Health Care
  • ATEC Health Care
  • Exchange
  • DAWN Nasdaq
  • ATEC Nasdaq
  • Market Cap
  • DAWN 1.6B
  • ATEC 1.4B
  • IPO Year
  • DAWN 2021
  • ATEC 2006
  • Fundamental
  • Price
  • DAWN $13.34
  • ATEC $10.21
  • Analyst Decision
  • DAWN Strong Buy
  • ATEC Strong Buy
  • Analyst Count
  • DAWN 7
  • ATEC 11
  • Target Price
  • DAWN $36.17
  • ATEC $17.82
  • AVG Volume (30 Days)
  • DAWN 1.3M
  • ATEC 3.0M
  • Earning Date
  • DAWN 10-30-2024
  • ATEC 10-30-2024
  • Dividend Yield
  • DAWN N/A
  • ATEC N/A
  • EPS Growth
  • DAWN N/A
  • ATEC N/A
  • EPS
  • DAWN N/A
  • ATEC N/A
  • Revenue
  • DAWN $101,953,000.00
  • ATEC $572,739,000.00
  • Revenue This Year
  • DAWN N/A
  • ATEC $27.98
  • Revenue Next Year
  • DAWN $44.21
  • ATEC $20.60
  • P/E Ratio
  • DAWN N/A
  • ATEC N/A
  • Revenue Growth
  • DAWN N/A
  • ATEC 27.21
  • 52 Week Low
  • DAWN $11.30
  • ATEC $4.88
  • 52 Week High
  • DAWN $18.07
  • ATEC $17.34
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 38.64
  • ATEC 73.90
  • Support Level
  • DAWN $12.86
  • ATEC $8.18
  • Resistance Level
  • DAWN $13.71
  • ATEC $8.42
  • Average True Range (ATR)
  • DAWN 0.77
  • ATEC 0.56
  • MACD
  • DAWN -0.25
  • ATEC 0.09
  • Stochastic Oscillator
  • DAWN 12.24
  • ATEC 97.30

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

About ATEC Alphatec Holdings Inc.

Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.

Share on Social Networks: